Ribonucleic Acid (RNA) Development platform

RNA therapeutic technology is nothing short of revolutionary. Its novelty lies in its unique ability to manipulate the human body as a natural bioreactor. This ground‐breaking discovery not only paved the way for innovative vaccines and infectious disease treatments but also revealed the vast potential of RNA‐based therapeutics to address a wide range of conditions like cancer, metabolic and genetic disorders, cardiovascular issues, and autoimmune diseases, as well as biosecurity applications.

For New Zealand to fully leverage the opportunities presented by RNA and to foster scientific expertise, capability, and self‐sufficiency, establishing an RNA Platform is of utmost importance. This Platform will be a dedicated science and technology hub, supporting the design and production of RNA therapeutics and mRNA vaccines within New Zealand. By bringing together experts and teams from diverse disciplines and institutions, it aims to strengthen New Zealand's capabilities in this cutting‐edge field. Moreover, it will establish connections with international efforts and developments, empowering local researchers to contribute to global advancements while enabling New Zealand companies to offer new RNA products and services.

The establishment of this Platform will not only elevate New Zealand's status in the field of RNA therapeutics but will also enhance its resilience. For example, in case of a future global pandemic, the country will be equipped with the ability to rapidly develop and manufacture vaccines not only for itself, but also for its Pacific neighbours. By enabling targeted research, the Platform will help build resilience for other potential crises, in addition to future pandemics.

In summary, the RNA Platform will be a catalyst for progress, innovation, and self‐reliance in RNA-based therapies, empowering New Zealand to contribute to global health efforts while safeguarding its own population and the broader Pacific community.